A Clinical Trial in Patients With Breast Cancer Susceptibility Gene (BRCA) Defective Tumours

Phase 2

Completed

• Conditions: Breast Cancer; Ovarian Cancer
• Interventions: Drug: 6-Mercaptopurine; Drug: Methotrexate

• Registration Number: NCT01432145
• Lead Sponsor: University of Oxford

Brief Summary

This study will evaluate the efficacy and safety of 6-mercaptopurine (6MP) in combination with methotrexate (MTX) in patients with breast or ovarian cancer who are known to have a BRCA (breast cancer gene) mutation.

Detailed Description

This study will evaluate the efficacy and safety of 6-mercaptopurine (6MP) in combination with methotrexate (MTX) in patients with breast or ovarian cancer who are known to have a BRCA (breast cancer gene) mutation. 6MP is used instead of thioguanine(6TG) as it is converted to the same cytotoxic moiety as 6TG, ie. thioguanine nucleotides, but with reduced toxic effects. Low dose methotrexate is used in combination with 6MP as it promotes the formation of thioguanine nucleotides.

Study Timeline

• Study Start: 2011-05
• Study First Submitted: 2011-08-10
• Study First Submitted QC: 2011-09-09
• Study First Posted: 2011-09-12
• Primary Completion: 2014-12
• Study Completion: 2015-05
• Status Verified: 2018-06
• Results First Submitted: 2018-06-21
• Results First Submitted QC: 2019-05-16
• Results First Posted: 2019-05-17
• Last Update Submitted: 2019-06-28
• Last Update Posted: 2019-07-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 74

Inclusion Criteria

1. Patients with proven BRCA1 or BRCA2 mutations and after appropriate exposure to standard treatment, as defined by:

   Breast Cancer

   • Patients with initially histologically or cytologically proven locally advanced or metastatic breast cancer who may have received up to 3 previous lines of chemotherapy in the locally advanced or metastatic breast cancer setting.
   • Patients must have previously had a taxane and an anthracycline in either the adjuvant or metastatic setting, provided that these were not contraindicated.
   • Patients with hormone responsive disease should have had at least 1 line of hormone therapy for metastatic disease.
   • Prior treatment with a poly-Adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitor is permissible.

   OR Ovarian Cancer

   • Patients with initially histologically or cytologically proven ovarian cancer.
   • Patients must have disease that is platinum resistant or in whom further platinum based therapy is inappropriate.
   • Prior treatment with a PARP inhibitor is permissible.

2. Patients must have measurable disease on computerized tomography (CT) or Magnetic resonance imaging (MRI) scan as defined by Response Evaluation Criteria In Solid Tumors (RECIST) criteria.

3. Age ≥18 years.

4. Eastern Cooperative Oncology Group (ECOG) performance score of 0-2.

5. Life expectancy >12 weeks.

6. Written informed consent.

7. Patient willing and able to comply with all protocol requirements.

8. No prior anti-cancer treatment in previous 4 weeks, other than palliative radiotherapy (RT).

9. Haematological and biochemical indices within the ranges shown below.

   • Laboratory Test Value required
   • Haemoglobin (Hb) > 10g/dL
   • White Blood Count (WBC) > 3x109/L
   • Platelet count > 100,000/μL
   • Absolute Neutrophil count > 1.5x109/L;
   • Serum bilirubin ≤ 2 x Upper limit normal (ULN)
   • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase (SGOT)) and alanine aminotransferase (ALT) or ALT ≤ 5 x ULN (liver metastasis)
   • or ≤ 3 x ULN (no liver metastasis)
   • Alkaline phosphatase ≤ 5 x ULN
   • Serum creatinine ≤ 1.5 x ULN

10. Ascites and pleural effusions must be drained prior to therapy.

Exclusion Criteria

1. Patients with any of the following contra-indications to thiopurines (6MP or 6TG) or methotrexate:

   • family history of severe liver failure;
   • alcoholism;
   • porphyria;
   • diffuse infiltrative pulmonary or pericardial disease;
   • known hypersensitivity to either trial agent.

2. Patients found to have a Low/Low genotype on thiopurine methyltransferase (TPMT) testing will be excluded.

3. Pregnant or breast-feeding women or women of childbearing potential unless highly effective methods of contraception are used.

4. Other active malignancy, with the exception of adequately treated in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin.

5. Patients known or tested to be serologically positive for Hepatitis B, Hepatitis C or human immunodeficiency virus (HIV).

6. Patients with active central nervous system (CNS) lesions are excluded (i.e., those with radiographically unstable, symptomatic lesions). However, patients treated with stereotactic therapy or surgery and/or whole brain radiotherapy are eligible if the patient remains without evidence of disease progression in brain ≥ 3 months prior to registration date . They must also be off corticosteroid therapy for ≥ 3 weeks prior to registration date.

7. Patients who have received anticancer agent(s) or an investigational agent within 28 days prior to study drug administration.

8. Subjects who have not recovered to within one grade level (not to exceed grade 2) of their baseline following a significant adverse event or toxicity attributed to previous anticancer treatment are excluded.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
6MP/MTX	6-Mercaptopurine	6-Mercaptopurine 55mg/m2 per day, and methotrexate 15mg/m2 per week
6MP/MTX	Methotrexate	6-Mercaptopurine 55mg/m2 per day, and methotrexate 15mg/m2 per week

Primary Outcome Measures

Name	Time	Method
Objective Response Rate to 6-mercaptopurine and Methotrexate (6MP/MTX) in This Patient Population.	8 weeks after start of treatment	1st stage: If less than 3/30 evaluable patients respond at 8 weeks the trial will be stopped for futility. If 3 or more out of 30 evaluable patients respond then a further 35 patients will be recruited (2nd stage) - this was met.; The proportion of patients responding to treatment (complete response, partial response or stable disease) at the second stage will be presented per Response Evaluation Criteria In Solid Tumours (RECIST) criteria version 1.1 measured radiologically with computerised tomography (CT) and/or magnetic resonance imaging (MRI); the same method is used at baseline and at follow-up: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Patients who yield progressive disease (PD) are classed as non-responders.

Secondary Outcome Measures

Name	Time	Method
Quality of Life - EuroQol Group, Five Dimensions, Three-level (EQ-5D-3L) Standardized Instrument for Measuring Generic Health Status	At the end of treatment or 12 months	Evaluated using the EQ-5D-3L questionnaire at baseline, 3 and 6 months, and at the end of treatment or 12 months, as well as using the ECOG performance status measure after each cycle

Trial Locations

Locations (1)

Churchill Hospital; 🇬🇧 Oxford, United Kingdom